Cancer Family
Childhood Neoplasm
CI-CAN-00000009Explore in graph →
PediatricNon-malignant312 active trials1 approved drugs68 evidence items
- NCIt
- C6283
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000009Explore in graph →
Clinical trials
1,503 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00093743 | Low-Dose Total-Body Irradiation and Fludarabine Phosphate Followed by Unrelated Donor Stem Cell Transplant in Treating Patients With Fanconi Anemia | completed | Phase 1 | 2 | Fred Hutchinson Cancer CenterOTHER | 1 | Feb 20, 2017 | clinicaltrials |
| NCT00052598 | Therapeutic Allogeneic Lymphocytes and Aldesleukin in Treating Patients With High-Risk or Recurrent Myeloid Leukemia After Undergoing Donor Stem Cell Transplant | terminated | Phase 1 / Phase 2 | 7 | Fred Hutchinson Cancer CenterOTHER | 1 | Feb 15, 2017 |
| clinicaltrials |
| NCT01204450 | Temsirolimus and Valproic Acid in Treating Young Patients With Relapsed Neuroblastoma, Bone Sarcoma, or Soft Tissue Sarcoma | terminated | Phase 1 | 7 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Dec 23, 2016 | clinicaltrials |
| NCT00450736 | Celecoxib and Radiation Therapy in Treating Patients With Stage II or Stage III Soft Tissue Sarcoma of the Arm, Hand, Leg, or Foot That Has Been Removed by Surgery | completed | Phase 1 | 3 | University of MiamiOTHER | 1 | Dec 15, 2016 | clinicaltrials |
| NCT01434849 | Timolol for the Prevention of Proliferation of Infantile Hemangioma (TiPPIH Trial)(TiPPIH) | terminated | Phase 1 | 26 | Alice K. GongOTHER | 1 | Nov 15, 2016 | clinicaltrials |
| NCT02897986 | Study of a Propranolol (HEMANGIOL®) and Oral Metronomic Vinorelbine (NAVELBINE®) Combination for Children and Teenagers With Refractory/Relapsing Solid Tumors(PROVIN) | unknown | Phase 1 | 54 | Assistance Publique Hopitaux De MarseilleOTHER | 1 | Sep 13, 2016 | clinicaltrials |
| NCT00049023 | Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors | completed | Phase 1 | 27 | O'Dorisio, M SOTHER | 1 | Jun 21, 2016 | clinicaltrials |
| NCT02031965 | Oncolytic HSV-1716 in Treating Younger Patients With Refractory or Recurrent High Grade Glioma That Can Be Removed By Surgery | terminated | Phase 1 | 2 | Pediatric Brain Tumor ConsortiumNETWORK | 1 | May 30, 2016 | clinicaltrials |
| NCT00720174 | Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma | completed | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | May 17, 2016 | clinicaltrials |
| NCT00326664 | AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors | completed | Phase 1 | 55 | National Cancer Institute (NCI)NIH | 1 | Mar 7, 2016 | clinicaltrials |
| NCT02444884 | MLN8237 to Treat Children With Relapsed/Refractory Solid Tumors | completed | Phase 1 | 54 | Children's Oncology GroupNETWORK | 0 | Feb 9, 2016 | clinicaltrials |
| NCT01748721 | MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma | completed | Phase 1 | 27 | MorphotekINDUSTRY | 1 | Jan 8, 2016 | clinicaltrials |
| NCT02533895 | Cancer Immune Therapy for the Treatment of Refractory Solid Tumours of Childhood | completed | Phase 1 | 67 | Activartis BiotechINDUSTRY | 1 | Dec 29, 2015 | clinicaltrials |
| NCT01403415 | Temsirolimus, Dexamethasone, Mitoxantrone Hydrochloride, Vincristine Sulfate, and Pegaspargase in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma | completed | Phase 1 | 13 | National Cancer Institute (NCI)NIH | 2 | Jul 10, 2015 | clinicaltrials |
| NCT01725191 | Tivantinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors | completed | Phase 1 | 36 | National Cancer Institute (NCI)NIH | 2 | Jul 2, 2015 | clinicaltrials |
| NCT01861990 | Valproic Acid in Childhood Progressive Brain Tumors | withdrawn | Phase 1 | 0 | Medical University of South CarolinaOTHER | 1 | May 22, 2015 | clinicaltrials |
| NCT00020150 | Temozolomide and O6-benzylguanine in Treating Children With Solid Tumors | completed | Phase 1 | — | National Cancer Institute (NCI)NIH | 1 | Apr 29, 2015 | clinicaltrials |
| NCT00669890 | Allogenic Stem Cell Transplantation in Patients With High Risk CD33+ AML/MDS/JMML(High Risk) | terminated | Phase 1 | 12 | New York Medical CollegeOTHER | 1 | Apr 22, 2015 | clinicaltrials |
| NCT00021216 | Bortezomib in Treating Children With Advanced Solid Tumors | completed | Phase 1 | 36 | National Cancer Institute (NCI)NIH | 1 | Apr 15, 2015 | clinicaltrials |
| NCT00343798 | A Pilot Study to Evaluate the Co-Infusion of Ex Vivo Expanded Cord Blood Cells With an Unmanipulated Cord Blood Unit in Patients Undergoing Cord Blood Transplant for Hematologic Malignancies | completed | Phase 1 | 23 | Fred Hutchinson Cancer CenterOTHER | 1 | Feb 11, 2015 | clinicaltrials |
| NCT01088763 | Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia | terminated | Phase 1 | 129 | National Cancer Institute (NCI)NIH | 2 | Nov 5, 2014 | clinicaltrials |
| NCT01164163 | INCB18424 in Treating Young Patients With Relapsed or Refractory Solid Tumor, Leukemia, or Myeloproliferative Disease | completed | Phase 1 | 49 | Children's Oncology GroupNETWORK | 1 | Oct 23, 2014 | clinicaltrials |
| NCT01919866 | Safety Study of CD3/CD19 Depleted Haploidentical Stem Cells | unknown | Phase 1 / Phase 2 | 120 | University Children's Hospital TuebingenOTHER | 2 | Oct 8, 2014 | clinicaltrials |
| NCT00003750 | Biological Therapy in Treating Children With Refractory or Recurrent Neuroblastoma or Other Tumors | completed | Phase 1 | 28 | Children's Oncology GroupNETWORK | 3 | Aug 8, 2014 | clinicaltrials |
| NCT00458744 | Talotrexin in Treating Young Patients With Recurrent Solid Tumors or Leukemia That is Recurrent or Does Not Respond to Treatment | withdrawn | Phase 1 | 0 | Children's Oncology GroupNETWORK | 0 | Aug 8, 2014 | clinicaltrials |
| NCT00107458 | Valproic Acid in Treating Young Patients With Recurrent or Refractory Solid Tumors or CNS Tumors | completed | Phase 1 | 26 | Children's Oncology GroupNETWORK | 2 | Aug 7, 2014 | clinicaltrials |
| NCT00946335 | ABT-888 and Temozolomide in Treating Young Patients With Recurrent or Refractory CNS Tumors | completed | Phase 1 | 31 | National Cancer Institute (NCI)NIH | 1 | Jul 9, 2014 | clinicaltrials |
| NCT00002947 | Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer | terminated | Phase 1 | 35 | Yale UniversityOTHER | 1 | Jul 2, 2014 | clinicaltrials |
| NCT00609141 | IMC-A12 in Treating Young Patients With Relapsed or Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor or Other Solid Tumor | completed | Phase 1 | 34 | National Cancer Institute (NCI)NIH | 1 | Jun 19, 2014 | clinicaltrials |
| NCT00217412 | Vorinostat With or Without Isotretinoin in Treating Young Patients With Recurrent or Refractory Solid Tumors, Lymphoma, or Leukemia | completed | Phase 1 | 60 | National Cancer Institute (NCI)NIH | 1 | Jun 17, 2014 | clinicaltrials |
| NCT00104962 | Lenalidomide in Treating Young Patients With Relapsed or Refractory Solid Tumors or Myelodysplastic Syndromes | completed | Phase 1 | 24 | National Cancer Institute (NCI)NIH | 1 | Jun 11, 2014 | clinicaltrials |
| NCT00042991 | Gefitinib and Radiation Therapy in Treating Children With Newly Diagnosed Gliomas | completed | Phase 1 / Phase 2 | 69 | National Cancer Institute (NCI)NIH | 1 | May 28, 2014 | clinicaltrials |
| NCT00095940 | Lapatinib in Treating Young Patients With Recurrent or Refractory Central Nervous System Tumors | completed | Phase 1 / Phase 2 | 52 | National Cancer Institute (NCI)NIH | 1 | May 23, 2014 | clinicaltrials |
| NCT00079339 | Tipifarnib and Radiation Therapy in Treating Young Patients With Brainstem Glioma | completed | Phase 1 / Phase 2 | 51 | National Cancer Institute (NCI)NIH | 1 | May 15, 2014 | clinicaltrials |
| NCT01240538 | Viral Therapy in Treating Young Patients With Relapsed or Refractory Solid Tumors | completed | Phase 1 | 26 | National Cancer Institute (NCI)NIH | 2 | May 13, 2014 | clinicaltrials |
| NCT00008424 | Irinotecan in Treating Children With Refractory or Advanced Solid Tumors Who Are Receiving Anticonvulsants | completed | Phase 1 | 7 | Children's Oncology GroupNETWORK | 3 | May 5, 2014 | clinicaltrials |
| NCT00933985 | Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia | terminated | Phase 1 | 22 | National Cancer Institute (NCI)NIH | 2 | May 1, 2014 | clinicaltrials |
| NCT00880282 | Cixutumumab and Temsirolimus in Treating Younger Patients With Solid Tumors That Have Recurred or Not Responded to Treatment | completed | Phase 1 | 39 | National Cancer Institute (NCI)NIH | 2 | Apr 29, 2014 | clinicaltrials |
| NCT01231919 | MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia | completed | Phase 1 | 45 | National Cancer Institute (NCI)NIH | 2 | Apr 29, 2014 | clinicaltrials |
| NCT01141244 | Temsirolimus, Irinotecan Hydrochloride, and Temozolomide in Treating Younger Patients With Relapsed or Refractory Solid Tumors | completed | Phase 1 | 72 | National Cancer Institute (NCI)NIH | 2 | Apr 10, 2014 | clinicaltrials |
| NCT01655875 | AMD3100 for Sensitizing in Allogeneic Blood or Marrow Transplant for Chemotherapy Resistant Pediatric Acute Leukemia(BMTAMD3100) | terminated | Phase 1 | 1 | Emory UniversityOTHER | 1 | Apr 7, 2014 | clinicaltrials |
| NCT00822458 | GDC-0449 in Treating Young Patients With Medulloblastoma That is Recurrent or Did Not Respond to Previous Treatment | completed | Phase 1 | 34 | National Cancer Institute (NCI)NIH | 1 | Apr 2, 2014 | clinicaltrials |
| NCT00101205 | Oxaliplatin, Ifosfamide and Etoposide in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma | terminated | Phase 1 | 40 | National Cancer Institute (NCI)NIH | 1 | Feb 24, 2014 | clinicaltrials |
| NCT00622414 | Aflibercept in Treating Young Patients With Relapsed or Refractory Solid Tumors | completed | Phase 1 | 27 | National Cancer Institute (NCI)NIH | 1 | Feb 24, 2014 | clinicaltrials |
| NCT00006095 | Combination Chemotherapy in Treating Children With Solid Tumors That Have Not Responded to Previous Therapy | completed | Phase 1 | 20 | Children's Oncology GroupNETWORK | 2 | Feb 21, 2014 | clinicaltrials |
| NCT00006463 | Ecteinascidin 743 in Treating Children With Refractory Solid Tumors | completed | Phase 1 | 13 | Children's Oncology GroupNETWORK | 3 | Feb 21, 2014 | clinicaltrials |
| NCT00070473 | Pemetrexed Disodium in Treating Young Patients With Recurrent Solid Tumors | completed | Phase 1 | 33 | Children's Oncology GroupNETWORK | 2 | Feb 20, 2014 | clinicaltrials |
| NCT00458731 | Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma | completed | Phase 1 | 57 | National Cancer Institute (NCI)NIH | 1 | Feb 19, 2014 | clinicaltrials |
| NCT01273090 | Imetelstat Sodium in Treating Young Patients With Refractory or Recurrent Solid Tumors or Lymphoma | completed | Phase 1 | 34 | Children's Oncology GroupNETWORK | 2 | Jan 30, 2014 | clinicaltrials |
| NCT02050243 | The Use of 5-aminolevulinic Acid (ALA) as an Intraoperative Tumor Marker for Resection of Pediatric Central Nervous System (CNS) Tumors(5-ALA) | unknown | Phase 1 / Phase 2 | 100 | Tel-Aviv Sourasky Medical CenterOTHER_GOV | 1 | Jan 30, 2014 | clinicaltrials |
Data updated 23 days agoSource updated Feb 20, 2017source: clinicaltrials